Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Neurotrophin Stories

2013-10-30 15:57:46

Interestingly, a recent study found that ischemic stress causes hyperglycemia and may worsen ischemic neuronal damage. In addition, decreased insulin sensitivity after ischemic stress seems to be involved in the development of post-ischemic glucose intolerance. However, the involvement of brain-derived neurotrophic factor in the development of glucose intolerance following ischemic stress still remains unclear. Xiaoliang Shu and colleagues from the Affiliated Dongfang Hospital of Tongji...

2013-10-23 12:29:31

LA JOLLA, Calif., Oct. 23, 2013 /PRNewswire/ -- "Stem cell therapy is an enthralling new achievement for the management of Parkinson's disease," said Dr. Stacy, the Vice Dean for Clinical Research, Neurology at Duke University School of Medicine. According to the Michael J. Fox Foundation, Parkinson's disease in the U.S. alone affects one in 100 people over 60 and 60,000 new cases will be diagnosed this year. Additionally, today's best Parkinson's drug was discovered in 1967. Fast...

Brain Health Boosted By Molecule Produced During Endurance Exercise
2013-10-11 06:49:14

April Flowers for redOrbit.com - Your Universe Online Exercise is good for nearly every part of your body, including your brain. According to researchers led by Harvard Medical School, a molecule called irisin is produced in the brain during endurance exercise and apparently has neuroprotective effects. The research team, led by Dr. Bruce Spiegelman of the Dana-Farber Cancer Institute and Harvard Medical School, artificially increased the levels of irisin in the blood to activate genes...

2013-04-22 22:22:51

Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain. Parkinson's is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the...

2013-02-28 08:29:48

SUNNYVALE, Calif., Feb. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Dr. John W. Commissiong, Chief Scientific Officer, will be presenting data generated in six hydroxydopamine (6-OHDA) rodent models of Parkinson's disease at the 15(th) Annual Meeting of the...

2013-02-25 12:25:06

SUNNYVALE, Calif. and ALACHUA, Fla., Feb. 25, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced that the companies will be making a joint poster presentation March 6-7, 2013 at The...

2013-02-13 15:04:21

In the journal PLoS Biology, a team of scientists reports experiments showing how the gene defect of Angelman syndrome disrupts neurological processes that may be needed for memory and learning. In tests in mice, the team showed that a novel compound could restore the healthy processes. In a new study in mice, a scientific collaboration centered at Brown University lays out in unprecedented detail a neurological signaling breakdown in Angelman syndrome, a disorder that affects thousands of...

2013-02-04 12:25:14

SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today reported that upon further analysis of the data reported on January 9th, 2013, the striatal reinnervation (densitometry) data produced in the 6 hydroxydopamine (6-OHDA) neurorestoration rat model of...

2013-01-28 08:35:54

SUNNYVALE, Calif., Jan. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced the launch of the Company's new website at www.amarantus.com. "2012 was an exceptionally productive year for Amarantus with the acquisition of two diagnostic platforms to expand our...

2013-01-10 12:24:22

SUNNYVALE, Calif., Jan. 10, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with protein misfolding and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF), today announced that a corporate presentation made by President & CEO Gerald E. Commissiong on Wednesday January 9, 2013 at Biotech Showcase 2013 is now...